Hyam I. Levitsky, M.D.
Juno Therapeutics, Seattle, WA, and The Johns Hopkins University School of Medicine, Baltimore, MD
Dr. Hyam I. Levitsky is the executive vice president, research, and the chief scientific officer at Juno Therapeutics and adjunct professor of oncology, medicine, and urology at The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. He was the head of cancer immunology experimental medicine at Roche before this position. Dr. Levitsky's laboratory research has focused on basic studies of antigen processing and presentation, T cell co-stimulation, T cell priming versus tolerance, and the evolution of tumor-specific immunity during immune reconstitution. He is a co-inventor of genetically modified GM-CSF secreting tumor cell vaccines (GVAX). At Johns Hopkins, Dr. Levitsky has been a pioneer in the integration of therapeutic cancer vaccines during immune reconstitution following high dose chemotherapy and stem cell transplantation.
Dr. Levitsky has served on the Board of Directors of Antigenics since 2006, and is currently on the Scientific Advisory Boards of Celldex, Dendreon, and Johnson & Johnson. Dr. Levitsky has received numerous awards for his research, including the Stohlman Scholars Award from the Leukemia and Lymphoma Foundation of America, The Senior Research Award from the Multiple Myeloma Research Foundation, Research Awards from the CapCURE Foundation, the American Cancer Society, and the National Institutes of Health. In 2001, he was elected to the American Society for Clinical Investigation. Dr. Levitsky received his undergraduate education at the University of Pennsylvania, and his medical degree at the Johns Hopkins University School of Medicine.